ABOUT US | My Site

What is ART-TG ?

The Technological Research Accelerator in Genomic Therapy (ART-TG) is a biomedical research center established by Inserm, the french national biomedical institution, to promote excellence in gene therapy research.

Our mission:

Advancing novel cell and gene therapy concepts towards clinical trials by bridging a gap between researchers/clinicians and industries.

What do we provide ?

We are a multi-disciplinary team with R&D expertise in molecular and cellular biology, virology, immunology, hematology and gene therapy.

We offer a unique capacity for lentiviral vector bioproduction process development and provide the pharmaceutical knowledge to develop ATMPs for clinical trials.

Our translational research activities are conducted through our integrator program, providing the quality management that is essential for IND-enabling studies.

Our collaborative research is funded by national or international grants (see below).

We also provide specialized R&D services for the production of lentiviral vectors and for the characterization of gene-modified cells.

Domains of interest:

-Two fields in which gene therapy has high innovation potential:

immunotherapy (e.g. gene-modified B cells for cancer or infectious diseases)

genetic disorders (e.g. base editing for sickle cell disease)

-Technologies directed to the genome (lentiviral gene addition or CRISPR gene editing), for durable corrective effects and requiring specific risk assessments.

Our location:

Within the Genopole campus, south of Paris, France.

What is the "integrator" program ? :

Through the France 2030 program, the french government supports the "integrator in biotherapy/bioproduction" program capable of addressing the challenges of industrial production of biomedicines. We have received the label "Integrator" since 2020.

Inserm Transfert accompanies the partnerships of ART-TG.

Contact us:
ART-TG seeks partners looking to innovate in the field of genomic therapy.

click here for inquiries